About BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:BCRX
- CUSIP: 09058V10
- Web: www.biocryst.com
- Market Cap: $386.05 million
- Outstanding Shares: 80,428,000
- 50 Day Moving Avg: $5.25
- 200 Day Moving Avg: $5.54
- 52 Week Range: $3.75 - $9.25
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.15
- P/E Growth: -0.34
- Annual Revenue: $29.28 million
- Price / Sales: 13.18
- Book Value: $0.30 per share
- Price / Book: 16.00
- EBITDA: ($42,940,000.00)
- Net Margins: -160.97%
- Return on Equity: -276.62%
- Return on Assets: -44.43%
- Debt-to-Equity Ratio: 0.94%
- Current Ratio: 1.57%
- Quick Ratio: 1.54%
- Average Volume: 1.55 million shs.
- Beta: 3.37
- Short Ratio: 17.05
Frequently Asked Questions for BioCryst Pharmaceuticals (NASDAQ:BCRX)
What is BioCryst Pharmaceuticals' stock symbol?
BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."
How were BioCryst Pharmaceuticals' earnings last quarter?
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The business had revenue of $3.10 million for the quarter, compared to analysts' expectations of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The company's quarterly revenue was down 35.4% on a year-over-year basis. During the same period last year, the business earned ($0.22) earnings per share. View BioCryst Pharmaceuticals' Earnings History.
When will BioCryst Pharmaceuticals make its next earnings announcement?
Where is BioCryst Pharmaceuticals' stock going? Where will BioCryst Pharmaceuticals' stock price be in 2017?
10 brokers have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $9.25 in the next twelve months. View Analyst Ratings for BioCryst Pharmaceuticals.
What are analysts saying about BioCryst Pharmaceuticals stock?
Here are some recent quotes from research analysts about BioCryst Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. " (8/10/2017)
- 2. Needham & Company LLC analysts commented, "Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."" (5/19/2017)
Are investors shorting BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 10,746,206 shares, a decrease of 25.1% from the September 15th total of 14,348,677 shares. Based on an average daily trading volume, of 2,214,130 shares, the days-to-cover ratio is currently 4.9 days. Approximately 11.1% of the company's stock are sold short.
Who are some of BioCryst Pharmaceuticals' key competitors?
Some companies that are related to BioCryst Pharmaceuticals include Keryx Biopharmaceuticals (KERX), La Jolla Pharmaceutical Company (LJPC), ZIOPHARM Oncology (ZIOP), CytomX Therapeutics (CTMX), Flexion Therapeutics (FLXN), PTC Therapeutics (PTCT), Vanda Pharmaceuticals (VNDA), Coherus BioSciences (CHRS), Intra-Cellular Therapies (ITCI), Aclaris Therapeutics (ACRS), Audentes Therapeutics (BOLD), Aduro Biotech (ADRO), Dova Pharmaceuticals (DOVA), MacroGenics (MGNX), Paratek Pharmaceuticals (PRTK), Synergy Pharmaceuticals (SGYP), G1 Therapeutics (GTHX) and Axovant Sciences Ltd (AXON).
Who are BioCryst Pharmaceuticals' key executives?
BioCryst Pharmaceuticals' management team includes the folowing people:
- Robert A. Ingram, Chairman of the Board
- Jon P. Stonehouse, President, Chief Executive Officer, Director
- Thomas R. Staab II, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer
- Yarlagadda S. Babu Ph.D., Senior Vice President - Drug Discovery
- Lynne M Powell, Senior Vice President, Chief Commercial Officer
- William P. Sheridan, Senior Vice President, Chief Medical Officer
- Alane P. Barnes, Vice President, General Counsel, and Corporate Secretary
- Fred E. Cohen Ph.D. M.D., Director
- Sanj K. Patel, Director
- George B. Abercrombie, Independent Director
How do I buy BioCryst Pharmaceuticals stock?
Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioCryst Pharmaceuticals' stock price today?
MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $4.80.
Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Hold Ratings, 7 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.70)|
|Consensus Price Target: ||$9.25 (92.71% upside)|Consensus Price Target History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/14/2017||Royal Bank Of Canada||Initiated Coverage||Sector Perform -> Sector Perform||$6.00||Low|
|9/6/2017||HC Wainwright||Reiterated Rating||Buy||$10.00||High|
|9/6/2017||J P Morgan Chase & Co||Boost Price Target||Overweight -> Neutral||$4.93 -> $9.00||High|
|9/6/2017||Jefferies Group LLC||Upgrade||Hold -> Buy||$5.00 -> $7.00||High|
|9/5/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$13.00 -> $15.00||High|
|8/8/2017||Noble Financial||Reiterated Rating||Buy||Low|
|5/19/2017||Needham & Company LLC||Reiterated Rating||Hold||Medium|
|2/16/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy||$11.00||N/A|
|1/23/2017||FBR & Co||Reiterated Rating||Outperform||N/A|
|12/16/2016||JMP Securities||Upgrade||Market Perform -> Outperform||$10.00||N/A|
|2/9/2016||Rodman & Renshaw||Lower Price Target||Buy||$24.00 -> $10.00||N/A|
|11/11/2015||Bank of America Corporation||Downgrade||Neutral -> Underperform||$12.00 -> $10.00||N/A|
|11/10/2015||Oppenheimer Holdings, Inc.||Reiterated Rating||Market Perform||N/A|
Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)Earnings History by Quarter for BioCryst Pharmaceuticals (NASDAQ BCRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/7/2017||Q2 2017||($0.19)||($0.21)||$5.79 million||$3.10 million||View||Listen|
|5/4/2017||Q1 2017||($0.20)||($0.19)||$6.13 million||$9.40 million||View||Listen|
|2/27/2017||Q416||($0.23)||($0.06)||$4.13 million||$9.00 million||View||Listen|
|11/7/2016||Q316||($0.24)||($0.16)||$5.94 million||$7.80 million||View||Listen|
|8/4/2016||Q216||($0.26)||($0.22)||$3.92 million||$4.80 million||View||N/A|
|5/5/2016||Q116||($0.23)||($0.31)||$5.42 million||$4.82 million||View||N/A|
|2/23/2016||Q415||($0.26)||($0.25)||$6.34 million||$4.60 million||View||Listen|
|11/5/2015||Q315||($0.20)||($0.20)||$6.77 million||$11.00 million||View||Listen|
|8/7/2015||Q215||($0.22)||$0.06||$7.10 million||$25.80 million||View||Listen|
|5/8/2015||Q115||($0.24)||($0.21)||$4.30 million||$6.80 million||View||Listen|
|2/18/2015||Q414||($0.20)||($0.16)||$3.64 million||$5.40 million||View||Listen|
|11/6/2014||Q314||($0.20)||($0.12)||$2.11 million||$3.20 million||View||Listen|
|8/5/2014||Q214||($0.19)||($0.23)||$2.32 million||$1.50 million||View||N/A|
|5/8/2014||Q114||($0.16)||($0.17)||$3.34 million||$3.50 million||View||N/A|
|2/26/2014||Q413||($0.08)||($0.09)||$8.81 million||$10.60 million||View||N/A|
|11/5/2013||Q313||($0.14)||($0.14)||$2.01 million||$2.40 million||View||N/A|
|8/8/2013||Q2 2013||($0.14)||($0.23)||$2.01 million||$0.82 million||View||N/A|
|5/7/2013||Q1 2013||($0.15)||($0.09)||$1.31 million||$3.60 million||View||N/A|
|2/19/2013||Q4 2012||($0.16)||($0.22)||$4.02 million||$4.10 million||View||N/A|
|11/8/2012||Q312||($0.22)||($0.19)||$4.63 million||$5.80 million||View||N/A|
Earnings Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)
2017 EPS Consensus Estimate: ($0.56)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Insider Ownership Percentage: 5.80%Insider Trades by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Institutional Ownership Percentage: 70.21%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/18/2017||Fred E Cohen||Director||Sell||54,250||$5.42||$294,035.00|| |
|3/20/2017||Thomas R Staab II||CFO||Sell||3,250||$9.20||$29,900.00|| |
|3/10/2017||Thomas R Staab II||Insider||Sell||3,250||$9.06||$29,445.00|| |
|3/8/2017||Thomas R Staab II||Insider||Sell||6,500||$8.43||$54,795.00|| |
|3/6/2017||Thomas R Staab II||Insider||Sell||3,250||$7.90||$25,675.00|| |
|12/19/2016||Thomas R Staab II||Insider||Sell||3,250||$7.45||$24,212.50|| |
|9/14/2016||Alane P Barnes||VP||Sell||8,357||$4.27||$35,684.39|| |
|8/25/2016||Yarlagadda S Babu||VP||Sell||30,000||$4.06||$121,800.00|| |
|8/16/2016||Bros. Advisors Lp Baker||Major Shareholder||Sell||4,046,590||$5.00||$20,232,950.00|| |
|8/12/2016||Thomas R Staab II||Insider||Sell||5,864||$5.18||$30,375.52|| |
|8/9/2016||Thomas R Staab II||Insider||Sell||14,577||$4.43||$64,576.11|| |
|1/28/2016||Bros. Advisors Lp Baker||major shareholder||Buy||88,345||$6.95||$613,997.75|| |
|1/22/2016||Bros. Advisors Lp Baker||major shareholder||Buy||106,800||$7.28||$777,504.00|| |
|1/20/2016||Bros. Advisors Lp Baker||major shareholder||Buy||52,695||$6.87||$362,014.65|| |
|1/19/2016||Bros. Advisors Lp Baker||major shareholder||Buy||92,200||$7.12||$656,464.00|| |
|1/15/2016||Bros. Advisors Lp Baker||major shareholder||Buy||200,000||$7.46||$1,492,000.00|| |
|12/21/2015||Thomas R Staab II||CFO||Sell||3,052||$10.86||$33,144.72|| |
|12/17/2015||Thomas R Staab II||CFO||Sell||3,000||$10.49||$31,470.00|| |
|7/20/2015||Thomas R Staab II||CFO||Sell||3,500||$16.50||$57,750.00|| |
|6/22/2015||Thomas R Staab II||CFO||Sell||3,750||$16.00||$60,000.00|| |
|6/19/2015||Alane P Barnes||VP||Sell||3,000||$15.00||$45,000.00|| |
|6/19/2015||Jon P Stonehouse||CEO||Sell||20,000||$15.02||$300,400.00|| |
|6/19/2015||Thomas R Staab II||CFO||Sell||16,375||$14.36||$235,145.00|| |
|6/19/2015||William P Sheridan||CMO||Sell||70,389||$15.05||$1,059,354.45|| |
|6/5/2015||Thomas R Staab II||CFO||Sell||6,000||$12.75||$76,500.00|| |
|5/18/2015||Thomas R Staab II||CFO||Sell||3,000||$11.00||$33,000.00|| |
|3/19/2015||Yarlagadda S Babu||VP||Sell||12,105||$10.16||$122,986.80|| |
|3/5/2015||Yarlagadda S Babu||VP||Sell||37,400||$10.59||$396,066.00|| |
|3/4/2015||Yarlagadda S Babu||VP||Sell||10,495||$10.50||$110,197.50|| |
|2/20/2015||Nancy J Hutson||Director||Buy||10,000||$10.27||$102,700.00|| |
|12/30/2014||William P Sheridan||CMO||Sell||128,399||$12.36||$1,587,011.64|| |
|12/29/2014||Thomas R Staab II||CFO||Sell||9,500||$12.56||$119,320.00|| |
|12/29/2014||William P Sheridan||CMO||Sell||105,295||$12.43||$1,308,816.85|| |
|8/27/2014||Thomas R Staab II||CFO||Sell||10,000||$13.58||$135,800.00|| |
|7/1/2014||Thomas R Staab II||CFO||Sell||3,125||$13.00||$40,625.00|| |
|6/23/2014||Thomas R Staab II||CFO||Sell||3,125||$12.49||$39,031.25|| |
|6/17/2014||Thomas R Staab II||CFO||Sell||3,125||$12.00||$37,500.00|| |
|3/14/2014||Thomas Staab II||CFO||Sell||3,125||$11.24||$35,125.00|| |
|3/6/2014||Kenneth Lee, Jr.||Director||Sell||12,665||$12.69||$160,718.85|| |
|11/12/2013||George Abercrombie||Director||Buy||3,000||$6.19||$18,570.00|| |
|8/1/2013||Felix Baker||Major Shareholder||Buy||1,136,364||$4.40||$5,000,001.60|| |
|3/5/2013||George B Abercrombie||Director||Buy||3,000||$1.23||$3,690.00|| |
|12/14/2012||Peder Jensen||Director||Buy||20,000||$1.51||$30,200.00|| |
Headline Trends for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Latest Headlines for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Loading headlines, please wait.
BioCryst Pharmaceuticals (BCRX) Chart for Monday, October, 23, 2017